A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Jankú, Alex A. Adjei, Cinta Hierro et al.|Cancers|2024Cited by 13
Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutationFilip Jankú, Alex A. Adjei, Faye M. Johnson et al.|Molecular Cancer Therapeutics|2019Cited by 7